Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerance of transurethral
photodynamic therapy (PDT) with QLT0074.
Secondary objectives are:
1. To determine if transurethral PDT with QLT0074 has a therapeutic effect on benign
prostatic hyperplasia (BPH), evaluated by the American Urological Association Symptom
Index (AUA SI), urinary flow rate (Qmax), and post-void residual volume (PVR).
2. To determine the extent of systemic exposure to QLT0074 following transurethral
intraprostatic injection.
3. To select up to two transurethral PDT drug-light regimens for further clinical
development.